A phase I study to evaluate the safety of the IQP-0528 vaginal gel in women as a potential anti-HIV topical microbicide

Trial Profile

A phase I study to evaluate the safety of the IQP-0528 vaginal gel in women as a potential anti-HIV topical microbicide

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2014

At a glance

  • Drugs IQP 0528 (Primary)
  • Indications HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 28 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top